Future of Red Biotechnology in China

Red biotechnology (RB) refers to the biotechnology applied in pharmaceutical production and it has become the most important part in biotechnology industry. About 60% of achievements in biotechnology in the world are applied in production of bio-pharmaceuticals. At present, RB products mainly include gene recombinant drugs, blood products, vaccines, diagnostic reagents, etc. What is the current production situation of different RB products in China?

Driven by its substantial environmental or economic benefits, China’s RB industry has witnessed fast development and has played an increasingly important role in Chinese economic growth. However, the overall development of China’s RB industry remains in growth stage, and still has an enormous gap compared with developed countries. What is the future trend of Chinese RB industry development? What are the relevant supporting policies on Chinese RB industry? What have been the popular cutting-edge technologies in China in recent years? Where are the investment opportunities and what is the investment mode in China?

What is covered in this report?

- Overview of China’s red biotechnology;
- Detailed analysis of each sub-categories of red biotechnologies in China: gene recombinant drugs, blood products, vaccines, diagnostic reagent, etc., in terms of market data, major players, technical suppliers, technologies or R&D situations;
- Future prospects of each category of red biotechnologies, with key influencing factors and commercial opportunities
- Profiles of major players and research institutes
- Related policies and regulations

What benefits will you get?

- Gain a clear understanding about the industry landscape and latest developments in R&D, production, technology advancement and future trends in China’s red biotechnology;?
- Keep informed of the precise development situation of key RB products with basic data and latest info;
- Gain reasonable and constructive suggestions on market opportunities in China’s RB fields;
- Figure out, current trend and future growth prospect of red biotechnology in China;
- Know more about how innovative players and research groups are carrying out innovation, collaboration and achieving commercial success in China.



Report Highlights
Companies Mentioned: Shenyang Sunshine Pharmaceutical Co., Ltd., Hualan Biological Engineering Inc., Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Kehua Bio-engineering Co., Ltd.,
[Fade out the market survey infos]

Executive summary

Methodology & sources

I Overview of red biotechnology in China

Introduction to red biotechnology

Role of red biotechnology in medicine industry

Overview of red biotechnology development

II Development environment of red biotechnology in China

II-1 Macro economic environment

II-2 Policy environment

II-3 Medicine industry development

II-4 Venture capital

III Market segments of red biotechnology industry in China

III-1 Gene recombinant drugs

III-1.1 Erythropoietin?EPO?

III-1.2 Insulin

III-1.3 G-CSF

III-1.4 Rh-GH

III-1.5 Interferon

III-1.6 Anti-tumor monoclonal antibody

III-2 Blood products

III-3 Human vaccines

III-4 Diagnostic reagent

III-4.1 Diagnostic reagent history in China

III-4.2 Current production situation in China

III-4.3 Producers information of Chinese diagnostic reagent

III-4.3.1 Biochemical diagnostic reagent

III-4.3.2 Immunodiagnostic reagent

III-4.3.3 Molecular diagnostic reagent

III-4.3.3.1 PCR reagent

III-4.3.3.2 Biochips

III-4.4 Forecast

III-5 Other red biotechnology based drugs

III-5.1 Antibiotic

III-5.1.1 Current antibiotic production in China

III-5.1.2 Penicillin production technology

III-5.1.3 Waste treatment technology

III-6 Forecast on supply & demand to the next 5~10 years

III-6.1 Forecast on gene recombinant market during 2010~2020

III-6.1.1 Supply of gene recombinant drugs during 2000~2020

III-6.1.2 Demand for gene recombinant drugs during 2009~2020

III-6.1.3 Difference between demand and supply during 2009~2020

III-6.2 Forecast on blood product market during 2010~2020

III-6.2.1 Supply of blood products during 2005~2020

III-6.2.2 Demand for blood products during 2009~2020

III-6.2.3 Difference between demand and supply during 2009~2020

III-6.3 Forecast on human vaccine market during 2010~2020

III-6.3.1 Supply of human vaccines during 2005~2020

III-6.3.2 Demand for human vaccines during 2009~2020

III-6.3.3 Difference between demand and supply during 2009~2020

III-6.4 Forecast on diagnostic reagent market during 2010~2020

III-6.4.1 Supply of diagnostic reagents during 2005~2020

III-6.4.2 Demand for diagnostic reagents during 2009~2020

III-6.4.3 Difference between demand and supply during 2009~2020

IV Cutting edge technology development in China

IV-1 Stem cell treatment

IV-2 Monoclonal antibody

IV-3 Diagnostic reagent

IV-4 Vaccine

V Geographical distribution of China’s red biotechnology industry

V-1 Regional distribution

V-2 Introduction to RB industrial clusters

V-3 Overview of major RB industrial bases

V-3.1 Changsha Natioanl Biomedical Industrial Base

V-3.2 Zhangjiang National Biomedical Industrial Base

V-3.3 Zhongguancun National Biomedical Industrial Base

V-3.4 Shenzhen National Biological Industry Base

V-3.5 Changchun National Biological Industry Base

V-3.6 Guangzhou National Biological Industry Base

V-3.7 Shijiazhuang National Biological Industry Base

V-4 Forecast on national biological industry base in the next 5~10 years

VI Analysis of main Chinese companies in red biotechnology

VI-1 Choice of main Chinese companies in red biotechnology industry

VI-2 Analysis on main Chinese companies in red biotechnology industry

VI-2.1 Company engaged in biotech drugs
- Shanghai FOSUN Pharmaceutical (GROUP) Co., Ltd.

VI-2.2 Companies engaged in blood products
- Shanghai RAAS Blood Products Co., Ltd.
- Hualan Biological Engineering,Inc.

VI-2.3 Company engaged in vaccine
- Beijing Tiantan Biological Products Co.,Ltd.

VI-2.4 Company engaged in bio-engineering drugs
- Beijing SL Pharmaceutical Co., Ltd.

VI-2.5 Company engaged in antibiotics
- Shangdong Lukang Pharmaceutical Co.,Ltd.

VI-2.6 Company engaged in diagnostic reagents
- Shanghai Kehua Bio-Engineering Co.,Ltd.

VII Main foreign involvement in China’s red biotechnology

VII-1 Foreign companies in China

VII-1.1 GlaxoSmithKline (China) Co., Ltd.

VII-1.2 Pfizer (China) Co., Ltd.

VII-1.3 Novartis (China) Co., Ltd.

VII-1.4 Sanofi Pasteur (China) Co., Ltd.

VII-2 Comparison of foreign companies and Chinese companies

VII-3 Forecast of foreign involvement in China in next 5~10 years

VII-3.1 Forecast on Novartis expansion in China

VII-3.2 Forecast on GSK expansion in China

VII-3.3 Forecast on Sanofi-aventis expansion in China

VIII Analysis of investment in the next 5 years

VIII-1 Investment opportunities in biopharmaceutical industry

VIII-1.1 Solid foundation of bio-pharmaceutical investment

VIII-1.2 Investment hotspots in China

VIII-2 Risk analysis of the investment in China’s red biotechnology

VIII-2.1 Risk from international environment

VIII-2.2 Risk from domestic environment

VIII-2.3 Estimation of bio-pharmaceutical investment risk in the next 5 years

IX Profiles of key players in China

IX-1 Companies

IX-1.1 Gene recombinant drugs

IX-1.2 Blood products

IX-1.3 Vaccine

IX-1.4 Diagnostic reagent

IX-2 Research institutes
[Fade out table of contents]

Table II-1.1 Annual benchmark lending rate of RMB
Table II-2 Relevant policies on bio-pharmaceutical industry in China, 2006-2009
Table II-3.1 Medicine industry output value in China, 2004-2008, billion USD
Table III-1.1.1 Market share of major EPO manufacturers, 2009
Table III-1.2.1 Three generations of insulin
Table III-1.2.2 Main rh-insulin manufacturers in China, 2009
Table III-1.3.1 Output of some G-CSF manufacturers, 2008
Table III-1.4.1 Market share of main rh-GH manufacturers in China, 2006-2008
Table III-1.5.1 Top four interferon manufacturers in China, 2009
Table III-1.5.2 Market share of main interferon manufacturers in China, 2006-2008
Table III-1.6.1 List of imported anti-tumor monoclonal antibody drugs
TableIII-1.6.2 List of domestic anti-tumor monoclonal antibody drugs
Table III-2.1 Some major human albumin manufacturers in China, 2010
Table III-2.2 Human albumin output of major manufacturers in China, 2008-2009
Table III-2.3 Human immunoglobulin for intravenous injection output of major manufacturers, 2009
Table III-3.1 Vaccines belonging to National Immunization Program, 2010
Table III-3.2 Average import and export prices of human vaccines, 2006-2009
Table III-3.3 Production situation of H1N1 Influenza A Vaccine in China, 2010 (Unit: thousand doses)
Table III-3.4 Monthly lot release volume of top 4 H1N1 Influenza A vaccine in China, Sep-Dec. 2009 (Unit: thousand doses)
Table III-3.5 All Inactivated Split Influenza vaccine lot release in China, 2009
Table III-3.6 Situation of domestic HBV lot release, 2007-2009 (unit: thousand doses)
Table III-3.7 Major manufacturers’ HBV lot release situation, 2009 (unit: thousand doses)
Table III-3.8 Lot release volume of some major human vaccines, 2007-2009
Table III-4.1 Comparison of three main diagnostic reagents
Table III-4.3.1 Major diagnostic reagent producers in China, 2008
Table III-4.3.1.1 Top 3 producers of biochemical diagnostic reagents in China, 2008
Table III-4.3.2.1 Some producers of immunodiagnostic reagent in China, 2008
Table III-4.3.3.1.1 Major PCR reagent producers in China, 2008
Table III-4.3.3.2.1 Some biochips producers in China, 2009
Table III-6.1.1.1 Supply of four gene recombinant drugs in China, 2000-2020
Table III-6.1.1.2 Supply of gene recombinant drugs in China, 2009-2020
Table III-6.1.2.1 Demand for gene recombinant drugs in China, 2009-2020
Table III-6.1.3.1 Demand & supply gap of gene recombinant drugs in China, 2009-2020
Table III-6.2.1.1 Supply of blood products in China, 2005-2020
Table III-6.2.2.1 Demand for blood products in China, 2009-2020
Table III-6.2.3.1 Demand & supply gap of blood products in China, 2009-2020
Table III-6.3.1.1 Supply of human vaccines in China, 2005-2020
Table III-6.3.2.1 Demand for human vaccines in China, 2009-2020
Table III-6.3.3.1 Demand & supply gap of human vaccines in China, 2009-2020
Table III-6.4.1.1 Supply of diagnostic reagents in China, 2005-2020
Table III-6.4.2.1 Demand for diagnostic reagents in China, 2009-2020
Table III-6.4.3.1 Demand & supply gap of diagnostic agents in China, 2009-2020
Table IV-3.1 Info about HIV diagnostic kit of different generation
Table V-1.1 Top 10 RB industrial regions by output value in China, 2008
Table V-1.2 Top 10 RB industry regions by profit, 2008
Table V-2.1 Seven National Biomedical Industrial Bases
Table V-3.1.1 Eight investment sectors of this Base
Table V-3.1.2.1 Incentives provided by the Base
Table V-3.1.2.2 High-quality research centers in the Base
Table V-3.2.2.1 Professional organizations
Table V-3.2.2.2 Venture Service Centre
Table V-3.3.2.1 Platform of Bio-technology
Table V-3.3.2.2 Animal base
Table V-3.3.2.3 R&D support
Table V-3.3.2.4 Main equipments and instruments in second-stage test workshop
Table V-3.5.1 Research centers
Table VI-1.1 Major listed bio-pharmaceutical companies and their achievements
Table VI-2.1.1 Employee structure in Shanghai FOSUN
Table VI-2.1.2 Business performance of Shanghai FOSUN by field and product, H1 2009
Table VI-2.1.3 Business performance of Shanghai FOSUN in different regions, H1 2009
Table VI-2.1.4 Financial indicators of Shanghai FOSUN, 2007- 2009
Table VI-2.2.1 Main products of Shanghai RAAS
Table VI-2.2.2 Employee structure of Shanghai RAAS
Table VI-2.2.3 Business performance of Shanghai RAAS by field and product, H1 2009
Table VI-2.2.4 Business performance of Shanghai RAAS in different regions, H1 2009
Table VI-2.2.5 Financial indicators of Shanghai RAAS, 2007 - 2009
Table VI-2.2.6 Employee structure of Hualan Biological
Table VI-2.2.7 Business performance of Hualan Biological by field and product, H1 2009
Table VI-2.2.8 Business performance of Hualan Biological in different regions, H1 2009
Table VI-2.2.9 Financial indicators of Hualan Biological, 2007- 2009
Table VI-2.3.1 Employee structure of Tiantan Biological
Table VI-2.3.2 Business performance of Tiantan Biological by product, H1 2009
Table VI-2.3.3 Business performance of Tiantan Biological, H1 2009
Table VI-2.3.4 Financial indicators of Tiantan Biological, 2007- 2009
Table VI-2.4.1 Employee structure of Beijing SL
Table VI-2.4.2 Business performance of Beijing SL by field and product, H1 2009
Table VI-2.4.3 Business performance of Beijing SL in different regions, H1 2009
Table VI-2.4.4 Financial indicators of Beijing SL, 2007-2009
Table VI-2.5.1 Employee structure of Shandong Lukang
Table VI-2.5.2 Business performance of Shandong Lukang by product, H1 2009
Table VI-2.5.3 Business performance of Shandong Lukang in different regions, H1 2009
Table VI-2.5.4 Financial indicators of Shandong Lukang, 2007- 2009
Table VI-2.6.1 R&D Events reflecting research capability of Shanghai Kehua, 2005~2009
Table VI-2.6.2 Four major diagnostic reagents of Shanghai Kehua
Table VI-2.6.3 Employee structure of Shanghai Kehua
Table VI-2.6.4 Business performance of Shanghai Kehua by field and product, H1 2009
Table VI-2.6.5 Business performance of Shanghai Kehua in different regions, H1 2009
Table VI-2.6.6 Financial indicators of Shanghai Kehua, 2007-2009
Table VII-1.1.2.1 Prescription medicines introduced by GSK China into China
Table VII-1.1.2.2 Vaccines introduced by GSK China into China
Table VII-1.1.2.3 OTC medicines marketed by GSK China in China
Table VII-1.1.2.4 Healthcare products of GSK China in China
Table VII-1.4.2.1 Bacterial diseases and viral diseases
Table VII-2.1 Financial performance comparison of Chinese and overseas biopharmaceutical companies, 2008-2009
Talbe VII-3.1.1 Industry sales and growth of Novartis, 2010~2015
Table VII-3.2.1 Industry sales and growth of GSK, 2009
Table VII-3.3.1 Sanofi-aventis industry sales and growth in 2008 and 2009
Table VIII-1.1.1 Main bio-industry policies
Table VIII-2.2.1 regulatory policies and main impacts
Table VIII-2.2.2 Important regulatory policies about blood product industry
Table VIII-2.2.3 Average R&D expenses of different era in the world
Table VIII-2.2.4 Domestic higher education graduates of biochemical pharmaceutical major
Table VIII-2.2.5 Employees of bio-chemical and bio-pharmaceutical enterprises
Table VIII-2.3.1 Estimated values of investment risks and EVBIR
Figure I.1 Output value of bio-pharmaceuticals in China, 2004-2009
Figure I.2 Proportion of bio-pharmaceuticals in China’s medicine industry, 2009
Figure I.3 RB industrial output value changes in the proportion of China’s GDP, 2004-2009
Figure II-1.1 China’s GDP growth, 2004-2009
Figure II-2.1 Per capita disposable income of urban residents in China, 2004-2009
Figure II-3.1 Medicine industry output value in China, 2004-Nov.2009
Figure II-4 Procedure of venture capital in bio-pharmaceutical industry
Figure III-1.1.1 EPO market value in China, 1999-2009
Figure III-1.1.2 Forecast on EPO market value, 2010-2014
Figure III-1.2.1 Global l insulin market value structure, 2009
Figure III-1.2.2 Insulin market value structure in China, 2009
Figure III-1.2.3 Output of rh-insulin in China, 2007-2009
Figure III-1.2.4 Number of global diabetes patients, 1985-2007
Figure III-1.2.5 Number of diabetes patients in China, 1978-2007
Figure III-1.2.6 Market value of insulin in China, 2005-2009
Figure III-1.2.7 Insulin import and export under HS code 29371200 in China, 2006-2009
Figure III-1.2.8 Insulin import and export under HS code 30043100 in China, 2006-2009
Figure III-1.2.9 Forecast on insulin market value, 2010-2014
Figure III-1.3.1 Procurement value of G-CSF of all Chinese hospitals, 2004-2008
FigureIII-1.4.1 Output of rh-GH in China, 2006-2009
Figure III-1.4.1 Market value of rh-GH in China, 2004-2009
Figure III-1.4.3 Forecast on rh-GH output, 2010-2014
FigureIII-1.4.4 Forecast on rh-GH market value, 2010-2014
Figure III-1.6.1 Global market value of anti-tumor monoclonal antibody, 2000-2009
Figure III-1.6.2 Proportion of bio-pharmaceuticals market value in drug market, 2001-2007
Figure III-1.6.3 Proportion of anti-tumor monoclonal antibody market value in bio-pharmaceuticals market, 2007
Figure III-1.6.4 Rituximab market value in China, 2003-2008
Figure III-1.6.5 Trastuzumab market value in China, 2003-2008
Figure III-2.1 Geographical distribution of blood product manufacturers in China, 2009
Figure III-2.2 Output of human albumin in China, 2004-2009
Figure III-2.3 Average yield of human albumin in China, 2004-2008
Figure III-2.4 Number Changes in active human albumin producers, 2004-2009
Figure III-2.5 Human albumin market value in China, 2005-2009
Figure III-2.6 Lot release volume of imported human albumin, 2007-2009
Figure III-2.7 Forecast on human albumin output, 2010-2014
Figure III-2.8 Forecast on human albumin market value, 2010-2014
Figure III-3.1 Import and export situation of Chinese human vaccines, 2006-2009
Figure III-3.2 Vaccines import volume shares of import origins, 2009
Figure III-3.3 Market value of China’s vaccine industry, 2006-2009
Figure III-3.4 Lot release volume of H1N1 Influenza A vaccine in China, 2009
Figure III-3.5 Forecast on China’s H1N1 Influenza A vaccine output, 2010-2014
Figure III-3.6 Situation of domestic Inactivated Split Influenza vaccine lot release, 2007-2009
Figure III-3.7 Market capacity of Inactivated Split Influenza vaccine in China, 2007-2009
Figure III-3.8 Proportion of homemade and imported seasonal influenza vaccine in China, 2009
Figure III-3.9 Market share of seasonal influenza vaccine producers by volume in China, 2009
Figure III-3.10 Lot release volume of imported seasonal influenza vaccine in China, 2007-2009
Figure III-3.11 Forecast on China’s influenza vaccine market capacity, 2010-2014
Figure III-3.12 Proportion of lot release volume of different HBV products, 2009
Figure III-3.13 China’s HBV market capacity, 2007-2009
Figure III-3.14 Lot release volume of imported HBV in China, 2007-2009
Figure III-3.15 Forecast on HBV market capacity in China, 2010-2014
Figure III-4.2.1 Output value of RB industry and diagnostic reagents industry in China, 2005- 2009
Figure III-4.2.2 Share of different diagnostic reagents in China by output value, 2008
Figure III-4.4.1 Forecast on output value of diagnostic reagent in China, 2010-2015
Figure III-5.1.1.1 Output of four products in antibiotic industry in China, 2005-2009
Figure III-5.1.2.1 Major procedures of three steps fermentation technology for penicillin production
Figure III-5.1.3.1 Waste treatment procedure in Chinese antibiotic industry
Figure IV-1.1 Major procedure of diabetes treatment with stem cell
Figure IV-2.1 Major procedure of monoclonal antibody production
Figure IV-4.1 Major procedure of avian influenza vaccine production
Figure VIII-1.1.1 Chinese population and growth rate, 2000-2009
Figure VIII-1.1.2 Elderly population and its proportion, 2000-2009
Figure VIII-1.1.3 Per capital income and growth rate in urban areas
Figure VIII-1.1.4 Per capital income and growth rate in rural areas
Figure VIII-2.2.1 Exchange rate of CNY against USD
Figure VIII-2.2.2 Industrialization process of bio-pharmaceutical products
[Fade out list of tables / figures]